Prevalence of adverse drug reaction with first-line drugs among patients treated for pulmonary tuberculosis

Abstract Adverse drug reactions (ADRs) to first-line anti-tuberculosis drugs are common and may cause associated morbidity and even mortality if not recognized early. 1–3 The overall prevalence of ADRs with first-line anti-tuberculosis drugs is estimated to vary from 8.0% to 85%. They are observed more commonly in the intensive phase and do not differ with intermittent or daily intake of anti-tuberculosis drugs. The occurrence of ADRs may be influenced by multiple factors and may range from mild gastrointestinal disturbances to serious hepatotoxicity, peripheral neuropathy, cutaneous adverse effects, etc. Early recognition and appropriate management of these adverse effects might determine adherence and treatment success.